2026-02-25T14:41:01+00:00 2025-06-30 135381590 BDO USA 200 PARK AVE 38TH FLOOR NEW YORK NY 10166 990 2024-07-01 954335088 LYMPHOMA RESEARCH FOUNDATION LYMP 2123492910 WALL ST PLAZA 88 PINE STREET 2400 NEW YORK NY 10005 MEGHAN GUTIERREZ CEO 2026-02-25 true PAUL HAMMERSCHMIDT P01384178 2128858000 2026-02-19 2024 2025-03-06 01:10:19Z MEGHAN GUTIERREZ WALL ST PLAZA 88 PINE STREET 2400 NEW YORK NY 10005 65290071 false X WWW.LYMPHOMA.ORG X 1991 CA TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. 22 22 47 20000 0 8648598 8904346 4272000 3728175 756160 1483381 248980 65280 13925738 14181182 3514100 2855823 0 4017428 5420452 0 2205810 5898277 6030355 13429805 14306630 495933 -125448 42834039 42720239 10073192 8187980 32760847 34532259 SEE SCHEDULE O false false 4613721 86000 3728175 EDUCATIONAL PROGRAMS AND SUPPORT SERVICES - THE LYMPHOMA RESEARCH FOUNDATION OFFERS A WIDE RANGE OF EDUCATIONAL PROGRAMS AND SUPPORT SERVICES FOR LYMPHOMA PATIENTS AND THEIR LOVED ONES, INCLUDING IN-PERSON AND VIRTUAL EDUCATION PROGRAMS AND EDUCATIONAL PUBLICATIONS. THE FOUNDATION HELPLINE PROVIDES LYMPHOMA PATIENTS AND THEIR LOVED ONES WITH INDIVIDUALIZED SUPPORT AND ANSWER ANY LYMPHOMA-RELATED QUESTIONS. THE FOUNDATION ALSO OFFERS A WIDE RANGE OF LYMPHOMA-FOCUSED EDUCATIONAL ACTIVITIES DESIGNED TO INCREASE THE KNOWLEDGE, SKILLS AND PERFORMANCE OF HEALTHCARE PROFESSIONALS AND TO MAXIMIZE THE QUALITY OF CARE FOR LYMPHOMA PATIENTS. 3912536 2769823 0 RESEARCH AND SCIENTIFIC PROGRAMS - THE LYMPHOMA RESEARCH FOUNDATION'S RESEARCH PROGRAM IS GUIDED BY ITS ELITE SCIENTIFIC ADVISORY BOARD, COMPRISED OF 45 EXPERT LYMPHOMA CLINICIANS AND SCIENTISTS FROM ACROSS NORTH AMERICA. THE FOUNDATION FUNDS RESEARCH INVESTIGATING EVERY LYMPHOMA SUBTYPE AND REMAINS COMMITTED TO SUPPORTING EARLY CAREER SCIENTISTS TO ENSURE THE BEST AND BRIGHTEST SCIENCE MINDS ARE DEDICATED TO RESEARCHING LYMPHOMA. IN ADDITION TO DIRECTLY FUNDING RESEARCH GRANTS, THE FOUNDATION FACILITATES COLLABORATION AND PARTNERSHIPS AMONG ACADEMIC SCIENTISTS, CLINICIANS, INDUSTRY, REGULATORY AGENCIES, AND PATIENTS. THROUGH ITS GLOBAL LYMPHOMA CONSORTIA AND SCIENTIFIC WORKSHOPS, THE FOUNDATION MOBILIZES THE RESEARCH COMMUNITY TO OVERCOME SYSTEMIC CHALLENGES AND SPEED THE PROGRESS OF THE DEVELOPMENT OF NEW TREATMENTS AND UNDERSTANDING OF THE VARIOUS SUBTYPES OF LYMPHOMA. 1716953 0 0 COMMUNITY OUTREACH AND ADVOCACY - THE LYMPHOMA RESEARCH FOUNDATION'S FOCUS INCLUDES COMMUNITY-BASED, PATIENT-CENTERED EDUCATION AND OUTREACH; INCREASING REPRESENTATION IN LYMPHOMA RESEARCH AND CLINICAL CARE AND COALESCING THE LYMPHOMA COMMUNITY AROUND AWARENESS INITIATIVES FOR THIS RARE DISEASE. THE FOUNDATION IS COMMITTED TO ADVOCATING ON BEHALF OF THE ENTIRE LYMPHOMA COMMUNITY IN SUPPORT OF THIS MISSION, WORKING COLLABORATIVELY WITH POLICYMAKERS, MEDICAL COMMUNITY, PATIENT ADVOCATES AND OTHER STAKEHOLDERS TO ADVANCE EFFORTS THAT WILL IMPROVE THE LIVES OF PEOPLE WITH LYMPHOMA. THE FOUNDATION SUPPORTS MEASURES WHICH WILL INCREASE FEDERAL FUNDING FOR LYMPHOMA RESEARCH AND ENSURE PATIENT ACCESS TO HIGH QUALITY CANCER CARE AND IMPROVED ANTI-CANCER TREATMENTS. THE FOUNDATION ALSO SUPPORTS EDUCATION AND OUTREACH EFFORTS TO IDENTIFY AND REACH UNDERSERVED PATIENT POPULATIONS. 10243210 true true false true false false false false false false true false false false true true true false false false false false false false true false false false true true false false false false false false false false false false true false false false false false false false false false true 65 0 true 47 true false false false false false true true false false false false false false X 22 22 false false false false false false false true true false false false true true true true true true true true false false CA FL GA AL HI IL KS KY MD MA MI MN MS NV NH NJ NM NY NC OR PA RI SC TN VA AR WV WI X X X HILLEL HYMAN COO 2123492910 WALL ST PLAZA 88 PINE STREET NEW YORK NY 10005 JEFF BLOCK VICE CHAIR AND TREASURER 2.0 X X 0 0 0 KIM METCALF VICE CHAIR 2.0 X X 0 0 0 LEIGH OLSEN SECRETARY 2.0 X X 0 0 0 STEVEN EICHBERG BOARD CHAIR 2.0 X X 0 0 0 ANN LACASCE MD MMSC BOARD MEMBER 1.0 X 0 0 0 ELLEN WALKER BOARD MEMBER (EFF. 2/2025) 1.0 X 0 0 0 HARRIET GREENBERG BOARD MEMBER 1.0 X 0 0 0 JOEL POLLICK BOARD MEMBER 1.0 X 0 0 0 JOHN A NELSON BOARD MEMBER 1.0 X 0 0 0 JOHN P LEONARD MD BOARD MEMBER 1.0 X 0 0 0 KEVIN SHEA BOARD MEMBER 1.0 X 0 0 0 KRISTI HENDRIKS BOARD MEMBER (EFF. 7/2024) 1.0 X 0 0 0 LAURENCE DOBOSH BOARD MEMBER 1.0 X 0 0 0 LINDSAY SPRINGER BOARD MEMBER 1.0 X 0 0 0 MICHAEL FROY BOARD MEMBER 1.0 X 0 0 0 MICHAEL WERNER BOARD MEMBER 1.0 X 0 0 0 PATRICIA KANE BOARD MEMBER (EFF. 6/2025) 1.0 X 0 0 0 PAUL MAJKOWSKI BOARD MEMBER (EFF. 6/2025) 1.0 X 0 0 0 RAMESH SUBRAHMANIAN BOARD MEMBER 1.0 X 0 0 0 ROBERT MCCAULEY BOARD MEMBER 1.0 X 0 0 0 SCOTT PANSKY BOARD MEMBER 1.0 X 0 0 0 WHITNEY NEIGHBORS BOARD MEMBER (EFF. 2/2025) 1.0 X 0 0 0 HILLEL HYMAN CHIEF OPERATING OFFICER (EFF. 12/2024) 35.0 X 14808 0 0 MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 45.0 X 364424 0 18342 LAURA WALLENSTEIN CHIEF PHILANTHROPY OFFICER 35.0 X 235033 0 45347 SARAH QUINLAN CHIEF PROGRAM OFFICER 35.0 X 213956 0 22864 CHRISTA BOGGIO CONTROLLER 45.0 X 192672 0 15618 LYNNE WINTER SENIOR PHILANTHROPIC ADVISOR 28.0 X 153446 0 14531 MICAH BANNER SENIOR DIRECTOR, INDIVIDUAL GIVING 35.0 X 171546 0 9478 NICHOLAS GUERCIO SENIOR DIRECTOR, MARKETING & COMMUNICATION 35.0 X 181070 0 12528 VICTOR GONZALEZ SENIOR DIRECTOR, PATIENT PROGRAMS 35.0 X 170659 0 20699 1697614 0 159407 12 false true false BUILD CONSULTING LLC C/O UNITED BANK LOCKBOX PO BOX 22 CHANTILLY VA 20153 TECHNOLOGY & IT CONSULTING 354374 ALLISON & PARTNERS ONE WORLD TRADE CENTER FLOOR 69 NEW YORK NY 10007 PR & MEDIA 304678 BLACKBAUD PO BOX 830413 PHILADELPHIA PA 19182 SOFTWARE & FISCAL & DEVELOPMENT 206405 THE MUNROE AGENCY 121 SOUTH BROAD STREET SUITE 1900 PHILADELPHIA PA 19107 INTEGRATED BRANDING & CREATIVE SERVICES 143567 RX 4 GOOD LLC 263 Delahow Street Daniel Island SC 29492 STRATEGIC PATIENT ADVOCACY 133053 7 2213934 6690412 444586 8904346 EDUCATION PROGRAMS & PATIENT SERVICES 812900 3728175 3728175 0 0 0 0 3728175 1236582 1236582 39340 39340 0 0 50724183 50477384 246799 0 246799 246799 631505 2213934 631505 MISCELLANEOUS REVENUE 900099 25940 25940 0 0 0 0 25940 14181182 3728175 0 1548661 2855823 2855823 1122845 636421 126832 359592 3392283 1913643 398812 1079828 93953 55731 6344 31878 327934 194523 22143 111268 483437 286764 32643 164030 34980 34980 65757 65757 30000 30000 226877 226877 1327456 902885 349772 74799 604077 550717 5430 47930 472514 364981 54348 53185 52756 30146 11305 11305 434793 248453 93170 93170 472254 384949 24420 62885 1700798 1612187 51231 37380 13128 7502 2813 2813 54433 31105 11664 11664 DUES AND SUBSCRIPTIONS 439104 137380 246177 55547 PROCESSING FEES 88008 88008 LICENSES AND PERMITS 8536 8536 REPAIRS AND MAINTENANCE 4884 4884 0 0 0 0 14306630 10243210 1857610 2205810 5283497 3970789 7240023 0 1451760 1252855 0 0 0 365437 296095 195658 175303 33483 20355 27312260 36392748 0 0 1147579 787397 42834039 42720239 720112 944372 7969260 6261310 191090 164393 0 1192730 817905 10073192 8187980 X 7993253 11704462 24767594 22827797 32760847 34532259 42834039 42720239 -125448 1896860 0 X false true true false X 10361473 9913811 12020634 8648598 8904346 49848862 0 0 10361473 9913811 12020634 8648598 8904346 49848862 13086131 36762731 234178 176115 322661 865613 1275922 2874489 0 0 22100 9384 227520 25940 284944 53008295 22384580 0.69353 0.6624 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - MISCELLANEOUS REVENUE, COLUMN A - 0.0, COLUMN B - 22100.0, COLUMN C - 9384.0, COLUMN D - 227520.0, COLUMN E - 25940.0, COLUMN F - 284944.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false true 30000 false true 51714 81714 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY EDUCATE AND CONTACT POLICY MAKERS AND THE PUBLIC ABOUT FEDERAL POLICIES AND PUBLIC HEALTH MATTERS AS THEY RELATE TO THE LYMPHOMA AND LARGER CANCER COMMUNITIES. 113640 93285 20355 61685 61685 0 20333 20333 0 20355 Federal Income Taxes OPERATING LEASE LIABILITY 817905 817905 X 17746549 1896860 1895384 0 3792244 13954305 226877 0 226877 14181182 15975137 1895384 0 1895384 14079753 226877 0 226877 14306630 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE FOUNDATION FOLLOWS GAAP, WHICH REQUIRES ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT. GAAP PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE FINANCIAL STATEMENTS IF THE POSITION IS "MORE LIKELY THAN NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. THE FOUNDATION IS INCORPORATED IN THE STATE OF CALIFORNIA AND IS EXEMPT FROM FEDERAL INCOME TAX UNDER IRC SECTION 501(C)(3), THOUGH IT IS SUBJECT TO TAX ON INCOME UNRELATED TO ITS EXEMPT PURPOSE, UNLESS THAT INCOME IS OTHERWISE EXCLUDED BY THE IRC. THE FOUNDATION HAS NO UNRELATED INCOME ASSOCIATED WITH ITS EXEMPT PURPOSE. THE FOUNDATION HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS, TO IDENTIFY AND REPORT UNRELATED INCOME, TO DETERMINE ITS FILING AND TAX OBLIGATIONS JURISDICTIONS FOR WHICH NEXUS WAS ESTABLISHED, AND TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. THE FOUNDATION HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. AS OF JUNE 30, 2025, THE FOUNDATION WAS NOT SUBJECT TO AN EXAMINATION BY A TAXING AUTHORITY. GALA and EP 1581117 1147117 434000 259063 11000 163937 GOLF 414013 321736 92277 61266 31011 11 850309 745081 105228 69637 35591 2845439 2213934 631505 389966 11000 230539 631505 0 true RESEARCH GRANT 24 2769823 PATIENT AID GRANT 430 86000 Schedule I, Part III, Column (b) Estimated Number Of Recipients PATIENT AID GRANT : THE FOUNDATION PROVIDES FINANCIAL ASSISTANCE TO LYMPHOMA PATIENTS WHO STRUGGLE TO PAY FOR EXPENSES RELATED TO THEIR LYMPHOMA TREATMENTS, SUCH AS MEDICAL BILLS AND TRANSPORTATION COSTS. THE FOUNDATION SUPPORT SERVICES STAFF REVIEWS THE APPLICATIONS, VALIDATES APPLICATION CRITERIA AND SUBMITS APPLICATIONS FOR PAYMENT APPROVAL TO DEPARTMENT LEADERSHIP. Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds THE FOUNDATION EXPERT SCIENTIFIC ADVISORY BOARD (SAB) CONDUCTS PEER REVIEW FOR ALL GRANT PROPOSALS AND RECOMMENDS THE HIGHEST-SCORING PROPOSALS TO THE FOUNDATION BOARD OF DIRECTORS FOR FUNDING. THE BOARD OF DIRECTORS THEN CONSIDERS AND APPROVES THE GRANTS WHICH ARE TO BE FUNDED. ONCE A GRANT IS APPROVED AND ACCEPTED BY THE GRANTEE, THE GRANTEE WILL BEGIN TO RECEIVE INSTALLMENTS BASED UPON THE PAYMENT SCHEDULE AS DICTATED IN THE GRANT CONTRACT. THE SAB AND LRF'S RESEARCH DEPARTMENT ANNUALLY REVIEW EACH GRANTEE'S PROGRESS AGAINST DELIVERABLES AND APPROVES THE CONTINUATION OF GRANT PAYMENTS. X X X false false false false false false false true false MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 326424 0 38000 0 0 0 18221 0 121 0 382766 0 0 0 LAURA WALLENSTEIN CHIEF PHILANTHROPY OFFICER 235033 0 0 0 0 0 11752 0 33595 0 280380 0 0 0 SARAH QUINLAN CHIEF PROGRAM OFFICER 213956 0 0 0 0 0 10698 0 12166 0 236820 0 0 0 CHRISTA BOGGIO CONTROLLER 182672 0 10000 0 0 0 3211 0 12407 0 208290 0 0 0 VICTOR GONZALEZ SENIOR DIRECTOR, PATIENT PROGRAMS 170659 0 0 0 0 0 8533 0 12166 0 191358 0 0 0 MICAH BANNER SENIOR DIRECTOR, INDIVIDUAL GIVING 171546 0 0 0 0 0 8577 0 901 0 181024 0 0 0 NICHOLAS GUERCIO SENIOR DIRECTOR, MARKETING & COMMUNICATION 166070 0 15000 0 0 0 0 0 12528 0 193598 0 0 0 LYNNE WINTER SENIOR PHILANTHROPIC ADVISOR 153446 0 0 0 0 0 1918 0 12613 0 167977 0 0 0 Schedule J, Part I, Line 7 Non-fixed payments SCHEDULE J, PART II, COLUMN (B)(II) REPORTS DISCRETIONARY INCENTIVE AMOUNTS THAT WERE APPROVED BY THE BOARD BASED UPON PERFORMANCE. 19 444586 Market value 0 false true false Schedule M, Part I Explanations of reporting method for number of contributions Securities - Publicly traded - NUMERICAL DATA HERE REPRESENTS THE TOTAL NUMBER OF CONTRIBUTIONS RECEIVED. Form 990, Part III, Line 1 THE LYMPHOMA RESEARCH FOUNDATION'S MISSION IS TO REALIZE THE PROMISE OF SCIENCE TO ERADICATE LYMPHOMA AND SERVE THE COMMUNITY TOUCHED BY THIS DISEASE. BY BRINGING TOGETHER THE PROMISE OF SCIENCE AND THE POWER OF PEOPLE, A FUTURE WITHOUT LYMPHOMA IS WITHIN OUR REACH. THE FOUNDATION IS COMMITTED TO FUNDING THE MOST PROMISING LYMPHOMA RESEARCHERS AND ADVANCING THE UNDERSTANDING OF THE MORE THAN 100 DIFFERENT SUBTYPES OF LYMPHOMA. LRF'S DISEASE-SPECIFICITY AND HYPER-FOCUS ON FINDING CURES FOR EVERY TYPE OF LYMPHOMA ENSURE THE NEXT GENERATION OF CANCER RESEARCHERS DEDICATE THEIR CAREERS TO STUDYING LYMPHOMA, AND WORLD-LEADING LYMPHOMA EXPERTS COLLABORATE AND ACCELERATE THE PACE OF SCIENTIFIC DISCOVERY. THE FOUNDATION ALSO OFFERS A WIDE RANGE OF SUPPORT SERVICES, EDUCATIONAL PROGRAMS, AND FREE PUBLICATIONS FOR PEOPLE WITH LYMPHOMA AND THEIR CARE PARTNERS. THE FOUNDATION INVESTS MILLIONS OF DOLLARS ANNUALLY IN ITS MISSION, ALL MADE POSSIBLE BY DONATIONS FROM ITS SUPPORTERS. THE FOUNDATION IS SUPPORTED BY TENS OF THOUSANDS OF VOLUNTEERS AND DONORS WHO CONTRIBUTE THEIR TIME AND TALENTS TO THE ORGANIZATION. THE FOUNDATION HAS EARNED THE TRUST OF INDIVIDUAL, PRIVATE FOUNDATIONS, PUBLIC COMPANIES, AND ORGANIZATIONS THAT FUNS ITS WORK BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. Form 990, Part VI, Line 15a LINE 15B - PROCESS TO ESTABLISH COMPENSATION THE ORGANIZATION SETS COMPENSATION IN A MANNER GIVING RISE TO A REBUTTABLE PRESUMPTION THAT THE COMPENSATION IS REASONABLE UNDER STANDARDS SET FORTH IN TREASURY REGULATIONS SECTION 53.4958-6. SALARIES OF THE SENIOR STAFF, INCLUDING THE CEO, ARE DETERMINED BASED UPON MARKET INFORMATION COMPARABLE TO THE POSITION IN OTHER NON-PROFIT ORGANIZATIONS. SENIOR STAFF COMPENSATION IS APPROVED BY THE CEO AND THE CHAIR OF THE BOARD OF DIRECTORS. THE CEO'S COMPENSATION IS APPROVED BY THE EXECUTIVE COMMITTEE (EC), WHICH HAS BEEN DULY AUTHORIZED BY THE BOARD AND CONSISTS OF INDEPENDENT MEMBERS, AND THE APPROVAL IS DOCUMENTED CONTEMPORANEOUSLY IN THE EC MINUTES. Form 990, Part VI, Line 11b Review of form 990 by governing body FORM 990 WAS PREPARED BY A NATIONAL ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. THE FORM 990 WAS REVIEWED IN DETAIL BY MANAGEMENT. AFTER REVIEW A FINAL DRAFT WAS PRESENTED TO THE AUDIT COMMITTEE AND FULL BOARD OF DIRECTORS FOR REVIEW AND COMMENT PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. Form 990, Part VI, Line 12c Conflict of interest policy THE CONFLICT OF INTEREST POLICY IS REVIEWED AND SIGNED ANNUALLY BY BOARD MEMBERS, OFFICERS AND STAFF. Form 990, Part VI, Line 19 Required documents available to the public THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS AND THE CONFLICT OF INTEREST POLICY ARE AVAILABLE TO THE PUBLIC UPON REQUEST. THE ORGANIZATION ALSO MAKES ITS FINANCIAL STATEMENTS AVAILABLE THEIR WEBSITE.